'Very over sol­d': Biotech brags about PhII Alzheimer's da­ta, but ex­perts are un­der­whelmed

In a field now de­fined by Bio­gen’s Aduhelm — and the storm of con­tro­ver­sy around it — what con­sti­tutes “in­dus­try-lead­ing” da­ta for an Alzheimer’s drug?

Alzheon, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER